Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda Pharmaceutical Company (Takeda) has launched Takelda combination tablets, a fixed-dose combination (FDC) of low-dose aspirin and Takepron (lansoprazole) for peptic ulcers in Japan.
Subscribe to our email newsletter
The tablets, a combination of 100mg aspirin and 15mg lansoprazole, are the first FDC drug in Japan to combine low-dose aspirin with a proton pump inhibitor.
The company said that number of patients taking low-dose aspirin for prevention of the recurrence of cerebral infarction or myocardial infarction is increasing.
As administration of low-dose aspirin may cause gastric or duodenal ulcers, preventing the onset of ulcers in these patients is important.
Patients with a history of gastric or duodenal ulcers are recommended to have a combined administration with a proton pump inhibitor.
Takeda director and senior vice president of Pharmaceutical Marketing Division Masato Iwasaki said patients who had experienced a cardiovascular event need to take low-dose aspirin in the long-term in order to prevent recurrence.
"We believe Takelda combination tablets can make a contribution to improved drug adherence among patients who have a history of gastric or duodenal ulcer and are taking low-dose aspirin together with Takepron," Iwasaki said.
"We strive to provide patients and medical practitioners with highly convenient therapeutic options."